BioMarin Pharmaceutical/ US09061G1013 /
| 8/9/2022 9:59:59 PM | Chg. +0.01 | Volume | Bid- | Ask- | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 95.70USD | +0.01% | 54,239 Turnover: 5.22 mill. |
-Bid Size: - | -Ask Size: - | 17.75 bill.USD | 0.00% | - |
Assets
| 2014 US GAAP in mill. USD |
2015 US GAAP in mill. USD |
2016 US GAAP in mill. USD |
2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Property and Equipment | 523.5000 | 704.2000 | 798.8000 | 896.7000 | 948.7000 | ||||||
| Intangible Assets | 156.6000 | 684 | 553.8000 | 517.5000 | 491.8000 | ||||||
| Long-Term Investments | - | - | - | - | - | ||||||
| Fixed Assets | - | - | - | - | - | ||||||
| Inventories | 199.5000 | 271.7000 | 355.1000 | 475.8000 | 530.9000 | ||||||
| Accounts Receivable | - | - | - | - | - | ||||||
| Cash and Cash Equivalents | 875.5000 | 397 | 408.3000 | 598 | 494 | ||||||
| Current Assets | 1,425.6000 | 1,089.6000 | 1,421.8000 | 2,207.1000 | 2,056.2000 | ||||||
| Total Assets | 2,490.5000 | 3,729.4000 | 4,023.7000 | 4,633.1000 | 4,427.1000 | ||||||
Liabilities
| 2014 US GAAP in mill. USD |
2015 US GAAP in mill. USD |
2016 US GAAP in mill. USD |
2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | ||||||
| Long-term debt | - | - | - | - | - | ||||||
| Liabilities to Banks | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | ||||||
| Provisions | - | 143.5000 | - | - | - | ||||||
| Liabilities | 962.6000 | 1,328.5000 | 1,257.4000 | 1,824.5000 | 1,459.2000 | ||||||
| Share Capital | - | - | - | - | - | ||||||
| Total Equity | 1,527.9000 | 2,400.8000 | 2,766.3000 | 2,808.7000 | 2,967.9000 | ||||||
| Minority Interests | - | - | - | - | - | ||||||
| Total liabilities equity | 2,490.5000 | 3,729.4000 | 4,023.7000 | 4,633.1000 | 4,427.1000 | ||||||
Income Statement
| 2014 US GAAP in mill. USD |
2015 US GAAP in mill. USD |
2016 US GAAP in mill. USD |
2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | 751 | 889.9000 | 1,116.9000 | 1,313.6000 | 1,491.2000 | ||||||
| Depreciation (total) | 18 | -17.7000 | -27 | 46.5000 | 48.8000 | ||||||
| Operating Result | -92.9000 | -110.7000 | -803.4000 | -14.7000 | -123.5000 | ||||||
| Interest Income | -30.7000 | -33.7000 | -32 | -27.8000 | -20.9000 | ||||||
| Income Before Taxes | -124.9000 | -154.7000 | -831.1000 | -35.9000 | -142.7000 | ||||||
| Income Taxes | 9.1000 | 17.1000 | -200.8000 | 81.2000 | -65.5000 | ||||||
| Minority Interests Profit | - | - | - | - | - | ||||||
| Net Income | -134 | -171.8000 | -630.2000 | -117 | -77.2000 | ||||||
Per Share
Cash Flow
| 2014 US GAAP in mill. USD |
2015 US GAAP in mill. USD |
2016 US GAAP in mill. USD |
2017 US GAAP in mill. USD |
2018 US GAAP in mill. USD |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow from Operating Activities | -73.5000 | -221.7000 | -227.8000 | -8.8000 | 20.2000 | ||||||
| Cash Flow from Investing Activities | 194.6000 | -1,179.6000 | -484 | -305.5000 | 264.4000 | ||||||
| Cash Flow from Financing | 185.7000 | 927.9000 | 727.1000 | 507.1000 | -388 | ||||||
| Decrease / Increase in Cash | 306.7000 | -478.4000 | 11.3000 | 189.7000 | -104 | ||||||
| Employees | 1,681 | 2,158 | 2,293 | 2,581 | 2,849 | ||||||